

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00, A01K 67/027, C12N 5/10		A1	(11) International Publication Number: WO 99/11772
			(43) International Publication Date: 11 March 1999 (11.03.99)
(21) International Application Number: PCT/IT98/00231			Advanced Biomedical Technologies, Consiglio Nazionale delle Ricerche, Via Ampere, 56, I-20131 Milano (IT).
(22) International Filing Date: 11 August 1998 (11.08.98)			(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
(30) Priority Data: MI97A001972 28 August 1997 (28.08.97) IT			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): CONSIGLIO NAZIONALE DELLE RICERCHE [IT/IT]; Piazzale Aldo Moro, 7, I-00185 Roma (IT).			
(72) Inventor: RONCUCCI, Romeo (deceased).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): SACCO, Maria, Grazia [IT/IT]; Institute of Advanced Biomedical Technologies, Consiglio Nazionale delle Ricerche, Via Ampere, 56, I-20131 Milano (IT). ZECCA, Luigi [IT/IT]; Institute of Advanced Biomedical Technologies, Consiglio Nazionale delle Ricerche, Via Ampere, 56, I-20131 Milano (IT). BROMLEY, Peter [CH/IT]; Institute of Advanced Biomedical Technologies, Consiglio Nazionale delle Ricerche, Via Ampere, 56, I-20131 Milano (IT). CLERICI, Libero, A. [IT/IT]; Joint Research Center, Environment Institute, I-21027 Ispra (IT). VEZZONI, Paolo [IT/IT]; Institute of			

Published

With international search report.


Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

In English translation (filed in Italian).

(54) Title: TRANSGENIC ANIMALS FOR THE STUDY OF BIOLOGICAL, PHYSICAL AND CHEMICAL TOXIC AGENTS

(57) Abstract

The invention provides non-human transgenic animals bearing regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents. Such sequences are linked to sequences of reporter genes useful for toxicological studies.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TRANSGENIC ANIMALS FOR THE STUDY OF BIOLOGICAL, PHYSICAL AND CHEMICAL TOXIC AGENTS

The present invention provides transgenic animals for the study of biological, physical and chemical toxic agents.

5 At present, toxicity tests can be carried out both in vivo and in vitro.

The industrials, the public opinion and the scientific community are strongly interested in the abolition of toxicity tests made on animals and therefore in their replacement with in vitro tests.

10 This target, however, is quite unrealistic at the moment, since no in vitro tests which can replace in vivo tests are available, either now or in the near future.

15 It is well known, in fact, that the substances under in vivo investigation often undergo metabolic modifications, which might significantly alter their toxicity profile, to an extent which would be unpredictable in in vitro tests.

20 On the other hand, in vivo studies always involve animal suffering and sacrifice.

However, it is possible to conceive genetically-engineered animal models which may simplify the determination of the toxicity of various agents and reduce the number of animals involved.

25 Recently, the use of transgenic animals as models for pharmacological studies has been proposed.

For example, EP 0 169 672 B1 describes transgenic animals bearing oncogenes like c-myc, suitable for the

study of tumors associated to the expression of such oncogenes, or bearing the human growth hormone gene fused to a metallothionein promoter, whereby, said promoter being an inducible promoter, it is possible to study the effect of the expression, upon induction, of the associated gene on the whole organism (Palmiter et al. (1983) Science 222, 809).

WO 91/15579 describes a method for studying mutagenesis in transgenic animals bearing DNA sequences which can easily be extracted and analysed for mutations.

The present invention provides non-human transgenic animals useful for toxicity studies.

Such animals are characterised in that they have regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents, functionally linked to sequences of reporter genes, whereby the expression of the latter sequences is controlled or induced by said regulatory sequences.

Among the regulatory sequences, the stress-promoter sequences, like the heat shock protein (hsp) promoters, are preferred, but also cytochrome-promoters of the p450-superfamily, as well as those promoters of other genes, like p53 gene, activated by biological, chemical or physical stress, can be cited.

Among suitable reporter genes, the growth hormone gene, which has been used in the experiments described below, is preferred, but also chloramphenicol acetyl transferase (CAT), green fluorescence protein (GFP) and β -galactosidase (LacZ) genes can be suitably employed.

The transgenic animals of the invention can be used

in a method for studying the toxicity induced by various agents.

In theory, any animal normally suitable for a toxicity test can be used in the method of the invention. In practice, non-human mammals, particularly
5 primates and rodents, are preferred.

Mice, in particular, are the most preferred.

Conventional methods can be used for the production of transgenic animals, including, for example, the
10 microinjection of recombinant DNA into embryonal cells or into pronuclei of one-cell stage embryos, the zygote, embryo cell, somatic cell or animal tissue infection with a virus, in particular with a retrovirus, according to what described, for example, in Hogan et al., Cold
15 Spring Harbor Laboratory Press, NY, 1986; Palmiter et al., Ann. Rev. Genet., 20: 465-499; 1986; Capecchi, Science, 244: 288-292, 1989.

The method for the in vivo assay of potential toxic compounds according to the present invention, comprises
20 exposing the animal to a chemical or physical agent for a time sufficient to induce the effect, and simply measuring the reporter gene expression. When the reporter gene encodes a protein secreted in the bloodstream, for instance, its hematic concentration, as
25 well as other chemical-clinical parameters associated with the effect caused by the activation of the stress promoter, could be detected.

According to the first aspect of the invention, a preferred embodiment is the production of transgenic
30 mice in which a construct has been inserted, which comprises a hsp promoter fused to growth hormone (GH)

gene (transgene), said promoter being described in Dreano et al. (Biotechnology 6:953, 1988 and Gene 49:1-8, 1986) and in Fishbach et al. (Cell Biol. Toxicol. 9:177-188, 1993). The latter publication reports that
5 the exposure to toxic metals of a stable fibroblast line, engineered with a construct containing the growth hormone gene under the control of hsp promoter, causes the secretion of the reporter gene in the medium.

According to the preferred embodiment of the
10 invention, the injury caused by the toxic agent is determined as the increase of GH plasma concentration versus the control.

This model has resulted particularly efficient and sensitive, especially in relation with toxic metals, but
15 it can suitably be used also for other classes of chemical toxic compounds, like endocrine disruptors, as well as for other physical or chemical agents, like radiations and electromagnetic fields.

The main advantages offered by the invention are:
20 the possibility to diminish animal suffering, since only low amounts of the test substances are used, surely lower than the dosages which could induce animal suffering or death; the reduction of the number of animals used in toxicological tests; the provision of a
25 model that is absolutely reliable for what concerns the metabolic modifications, which the toxic agents undergo in the organism, the interactions of toxic compounds with various organs and their final effects on cells, including the chronic effects. This model is
30 particularly useful for test reiterations and allows to monitor the agent's effect during long-lasting

5

treatments using always the same animal, thus eliminating the variability of the individual response. Further, several compounds can be studied using the same animal. Finally, such transgenic models can be used also for in vivo studies of toxicity kinetics of toxic compounds.

The second aspect of the invention concerns the possibility to obtain primary cultures of cells from different tissues of the transgenic animal, in which a recombinant DNA construct is integrated as described above, whereby a cell- or tissue-specific toxicity study can be carried out and the intracellular biochemical effects connected to toxicity can be evaluated under controlled conditions and in more detail during different stages of animal growth.

In this case, the in vitro assay comprises preparing primary cultures in conditions variable depending on the cell type, exposing said cultures to the toxic agent and monitoring the activation of the stress promoter through detection of the protein encoded by the reporter gene.

Referring to the above described transgenic mice bearing the hsp/GH construct, an embodiment of the second aspect of the invention consists for example in preparing primary cultures of fibroblasts, kidney, lung or bone marrow cells, hepatocytes or other, in their simultaneous or separate treatment with one or more toxic agents, and in the determination of GH secretion in the medium.

If, using the above assay, a tissue or a cell-type resulted sensitive to the toxic agent, a deeper

biochemical analysis could be made in order to find which cellular pathways are particularly involved in the toxicity.

Thus, according to a further aspect, the invention provides a method to carry out in vitro toxicity tests on primary cultures of somatic cells derived from a transgenic animal.

BRIEF DESCRIPTION OF THE FIGURES

Fig 1. Panel A: Southern blot analysis of transgenic heterozygous (lanes 1-4) and homozygous mice (lanes 5-7) and a non-transgenic control mouse (lane 8).

Panel B: RT-PCR with hGH specific primers of heat-shock activated liver cells from transgenic mice. Samples: RNA from cultured hepatocytes before (lane 1) and 30 min after (lane 2) heat shock in vitro; RNA from livers before (lane 3) and 30, 60, 90, minutes after heat shock (lanes 4-6). + and - represent the negative and positive controls respectively. Lanes 7 to 10 are the amplifications on non-retrotranscribed liver RNAs performed on the same samples as in lanes 3 to 6. M1: marker V, M2: 1 kb ladder.

Panel C: RT-PCR with HPRT specific primers performed on RNAs from the samples 1 to 6 as in panel B.

Fig. 2: Plasma levels of hGH (pg/ml) measured at different times in transgenic mice after thermal stress. Values represent the mean \pm SE; the number of mice tested for each time period is indicated by the number above each bar.

Fig. 3: Mean hGH plasma levels (pg/ml) \pm SE observed in transgenic mice injected i.p. with PBS and with various inorganic toxic compounds at the indicated

7

doses. Besides controls, are indicated: Rb: rubidium chloride; Hg: methylmercurium chloride; Cu: copper sulphate; Cd: cadmium chloride; As: sodium arsenite (2 doses)(below each bar is given the number of tested mice). The levels of significance are: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.005$

Fig. 4: Mean \pm SE of plasma hGH levels observed in transgenic mice subjected to two consecutive treatments, according to the following schema:

10

Group	First treatment (T_1)	Second treatment (T_2)	Time Interval ($T_1 - T_2$)
As ₁	As	As	10 days
As ₂	Cd	As	2 months
As ₃	Rb	As	2 months
Cu	Cu	Cu	2 months
Control	untreated	untreated	

20

The following examples better illustrate the invention:

EXAMPLE 1

Production and characterization of a transgenic mouse lineage

Transgenic mice were produced according to standard techniques (Hogan et al., "Manipulating the mouse embryo: a laboratory manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), by microinjecting 1-cell stage embryo pronuclei with a 1.4 kb EcoRI DNA fragment from p17hGH construct (described in Dreano et al., Biotechnology 6:953, 1988 and Gene

49:1-8, 1986), containing the human growth hormone cDNA as reporter gene, fused to the control region of the human Hsp70 promoter.

Mice were screened by Southern blot and/or PCR performed on tail DNA according to standard techniques. PCR was performed with the following primers: hGHL:GTGCAGTTCCTCAGGAGTGT; hGHR: CGAACTTGCTGTAGGTCTGC.

The amplification product was 171 bp long. Amplification conditions (35 cycles) were: 94°C for 20 sec, 58°C for 30 sec and 72°C for 20 sec. Heterozygous males and females were crossed and the homozygous progeny was identified by Southern blot, based on the intensity of the transgenic bands; their homozygosity was confirmed by checking the offspring when the homozygous male was mated to a non-transgenic partner. The mice used for the in vitro and in vivo experiments were always derived from a homozygous male bred with a non-transgenic CD-1 female.

Total RNA was extracted from different tissues (liver, spleen, lung, kidney, blood) of transgenic and control mice, according to standard techniques (Sambrook et al., "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Southern and Northern blot were performed according to standard techniques.

In order to evaluate the basal value of non-induced expression of the transgene, mice were analysed with Northern blot and with RT-PCR.

No expression was detected in lung, kidney, spleen, liver and peripheral blood lymphocytes of non-treated animals or of animals not-exposed to heat shock. The hGH

level in non-treated mice (control) was generally under the test detection limits, and when it was determined, it never exceeded 10 pg/ml.

EXAMPLE 2

5 In vivo heat shock treatment.

Eight transgenic mice obtained according to example 1 and four non-transgenic control mice were subjected to in vivo heat shock at 44°C for 30 min. Six additional unexposed transgenic mice were tested. Aliquots of blood
10 were taken before and 1, 3, 5, 7, and 24 hours after the heat shock.

In transgenic mice (Fig. 2) a specific increase of plasma hGH was detected with a peak three hour after treatment.

15 These results suggest that the integrated transgene does not affect in vivo the normal responsiveness of hsp promoter.

EXAMPLE 3

a) Inducibility of the hsp70/hGH transgene expression
20 in vivo by sodium arsenite and methylmercurium chloride.

Male transgenic mice obtained as described in example 1 were weighed, anesthetized with ether and injected intraperitoneally (i.p.) with NaAsO₂ dissolved in PBS, at a final dose of 2.5 or 5 mg/kg, or with 3.5
25 mg/kg CH₃HgCl dissolved in PBS. Control transgenic mice were injected with the same volume of PBS (about 200 µl/mouse).

Blood samples were recovered before injection and 1, 3, 5, 7 and 24 hours after treatment.

30 hGH plasma levels at different times and doses are shown in Fig. 3.

10

Both the tested doses of NaAsO_2 gave a clear and statistically significant response.

The response peaked after 3-5 hours and turned to the basal level 24 hours after injection.

5 CH_3HgCl gave hGH peaks after 5-7 hours and baseline hGH values 24 hours after injection.

b) Following the same procedure as described in a), hGH inducibility was evaluated in mice treated with rubidium chloride (18.5 mg/kg, c), copper sulfate (9
10 mg/kg, d) and cadmium chloride (4.7 mg/kg, e).

Results are reported in Fig. 3.

EXAMPLE 4

Inducibility of the hsp70/hGH transgene expression in vivo by repeated injections of toxic compounds.

15 Initially, 13 mice were treated as follows:

5 mice with As, 3 mice with Cd, 2 mice with Rb, 3 mice with Cu. After a period of 10 days to 2 months, the former three groups of mice were re-inoculated with As, the latter with Cu.

20 Blood samples were taken before and 3-5 hours after injection, i.e. at the times of highest response.

As shown in Fig. 4, after the first administration of the compound, the mice showed a response comparable to that observed in groups of mice treated as in example
25 3.

When retested after 10-60 days, a similar hGH increase was observed.

EXAMPLE 5

Embryonic fibroblast primary cultures-in vitro toxicity tests.
30

Homozygous transgenic mice obtained as described in

11

example 1 were crossed with CD-1 females. After 14 days, embryonic fibroblasts (EMFIS) were recovered from the fetuses according to the technique described by Robertson E.J., IRL Press, Oxford, 77-88, 1987.

5 Cells were cultured in DMEM supplemented with 10% FCS and antibiotics (pen/strep), in an incubator (CO₂:5%, 100% humidity). Culture medium was replaced every second day with pre-warmed (37°C) fresh culture medium. The cells were expanded for two passages and
10 then frozen at -80°C. For each experiment, cells were thawed, plated in 10 cm Petri dishes, left to grow and then re-seeded on 12 well plates until confluence.

 To evaluate the toxic effect of the compounds, cells were treated by substituting the culture medium
15 with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions. Cells were exposed to the toxic compound for either 5 or 24 hours and then the medium was replaced with fresh control medium for an additional 24 hours. At the end of
20 the treatment, culture media were collected and assayed for hGH secretion by enzyme immunoassay.

 Each treatment was performed in triplicate and the hGH determination was repeated twice for each plate. The results are expressed as pg of hGH/10⁶ cells. The
25 sensitivity of this method was approximately 2-4 pg/ml.

 As shown in the table, calcium and rubidium, known for their lack of toxicity at the tested concentrations, do not provoke hGH release in the medium.

 On the contrary, a significant release is induced
30 after 24 hours of chrome exposure, while copper gives a low response after 24 hours at the highest

12

concentrations. On the contrary, mercurium does not induce hGH release from fibroblasts at each tested concentration.

Finally, arsenic and cadmium, as expected, showed
5 clearly toxic.

EXAMPLE 6

Primary hepatocytes cultures-in vitro toxicity tests.

Transgenic male mice 8 weeks old were anesthetized
10 and their livers were perfused as described in Clerici et al., Mut. Res., 227:47-51, 1989, in order to collect hepatocytes. Hepatocytes were then seeded on 24 well plates (2×10^5 cells/well) and cultured in William's E medium supplemented with antibiotics (pen/strep) and 10%
15 FCS for 2 hours in order to allow them to attach to the bottom of the Petri dishes. The supernatant was then removed and the adherent cells were treated with the compounds dissolved in the medium.

To evaluate the toxic effect of the compounds,
20 cells were treated by substituting the culture medium with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions.

As shown in the table, calcium and rubidium do not induce hGH release by mature hepatocytes.

25 Chrome treatment induces a high response after 24 hours, while copper treatment causes release either after 5 or 24 hours at each concentration.

Mercurium induces a response at concentrations higher than 5×10^{-5} M, while arsenic and cadmium show
30 extremely toxic.

EXAMPLE 7

In vitro toxicity tests on kidney, lung and bone-marrow primary cultures.

Kidney and lung cells were recovered as described by Campbell, J. A. et al. ("Sister chromatid exchange analysis of mice following in vitro exposure to vinyl carbonate", In vitro Cell. Dev. Biol. 22: 443:448, 1986).

Briefly, kidneys were removed from the same animals subjected to liver perfusion, washed 3 times in PBS additioned with antibiotics and minced in 0.5 mm pieces with a sterile scalpel. After 1 hour of incubation in trypsin/collagenase (100U/ml) solution, the suspension was centrifuged twice for 5 min. at 50xg, plated in 100 mm Falcon dishes and cultured in McCoy's medium with 20% FCS, 2mM Glutamine and Pen/strep.

In order to collect lung cells, after liver perfusion the chest cavity was opened after liver perfusion to access the lungs. The trachea was cut with a scalpel and a 22-gauge catheter was inserted into the trachea to perfuse the lungs with trypsin/collagenase solution for 5 min. in order to help the disaggregation of this tissue. The cells were then trypsinized, seeded in 24 wells and left to grow until confluence in McCoy's medium with 20% FCS, 2mM Glutamine and antibiotics.

In order to prepare bone marrow primary cultures, bone marrow cells were flushed from the cavity of femurs and tibias with a syringe containing the culture medium. Cells were plated in 12 well plates with McCoy's medium with 20% FCS, 2mM Glutamine and antibiotics, and left to grow until the stromal cells reached confluence.

To evaluate the toxic effect of the compounds, the

14

same procedure was followed as in the above examples 5 and 6.

Results are reported in the Table.

Table
(A) Determination of hGH (pg/10⁶ cells) release and primary transgenic cultures viability
after 5-hour treatment

Compounds	Primary lines	hGH release			Viability		
		10 ⁻⁵ M	5x10 ⁻⁵ M	10 ⁻⁴ M	5x10 ⁻⁵ M	10 ⁻⁴ M	5x10 ⁻⁴ M
CaCl ₂	hepatocytes	nd	nd	nd	+	+	+
RbCl		nd	nd	nd	+	+	+
CrCl ₃		/	nd	nd	/	+	+
CuSO ₄		/	nd	80	/	+	+
K ₂ Cr ₂ O ₇		nd	65	94	+/-	-	-
CH ₃ HgCl		nd	nd	nd	+/-	-	/
CdCl ₂		309	452	57	+/-	-	-
NaAsO ₂		100	224	nd	+	+/-	/
CaCl ₂	Embryonic	/	nd	nd	/	+	+
RbCl	fibroblast	/	nd	nd	/	+	+
CrCl ₃		/	nd	nd	/	+	+
CuSO ₄		/	nd	6	/	+	+
K ₂ Cr ₂ O ₇		9	nd	nd	+/-	-	-
CH ₃ HgCl		/	nd	nd	/	-	/
CdCl ₂		250	85	45	+/-	-	-
NaAsO ₂		nd	113	19	+	+/-	/

continues

Kidney cells	CaCl ₂	/	nd	nd	/	+	+	+
	RbCl	/	nd	nd	/	+	+	+
	CrCl ₃	/	nd	15	/	+	+	+/-
	CuSO ₄	/	nd	nd	/	+	+	+/-
	K ₂ Cr ₂ O ₇	nd	nd	nd	+/-	+	+	/
	CH ₃ HgCl	10	nd	nd	+/-	+	+	/
	CdCl ₂	nd	nd	nd	+	-	-	/
	NaAsO ₂	22	17	28	+	-	-	/
Lungs cells	CaCl ₂	/	nd	127	/	+	+	+
	RbCl	/	28	191	/	+	+	+
	CrCl ₃	/	92	122	/	+	+	+
	CuSO ₄	/	nd	nd	/	+	+	+/-
	K ₂ Cr ₂ O ₇	nd	nd	nd	+/-	-	-	/
	CH ₃ HgCl	27	nd	nd	-	-	-	/
	CdCl ₂	nd	31	11	+/-	-	-	/
	NaAsO ₂	nd	37	249	+/-	-	-	/

hGH levels in untreated cells medium (controls) were not measurable after 5-24-hour incubation.

nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability;

- = 100% dead

(B) Determination of hGH (pg/10⁶ cells) release and primary transgenic coltures after 24-hour treatment.

Compounds	Primary lines	hGH release		Vitality			
		10 ⁻⁵ M	5x10 ⁻⁵ M	10 ⁻⁴ M	5x10 ⁻⁴ M	10 ⁻⁴ M	5x10 ⁻⁴ M
hepatocytes	CaCl ₂	nd	nd	nd	nd	+	+
	RbCl	nd	nd	nd	nd	+	+
	CrCl ₃	/	36	20	nd	+	-
	CuSO ₄	/	12	61	100	+	+/-
	K ₂ Cr ₂ O ₇	nd	nd	nd	nd	-	-
	CH ₃ HgCl	nd	63	103	/	-	/
	CdCl ₂	nd	nd	17	21	+/-	-
Embryonic fibroblast	NaAsO ₂	270	19	5	/	+/-	/
	CaCl ₂	/	nd	nd	nd	+	+
	RbCl	/	nd	nd	nd	+	+
	CrCl ₃	/	8	10	6	+	+
	CuSO ₄	/	nd	10	47	+	+
	K ₂ Cr ₂ O ₇	nd	nd	nd	nd	-	-
	CH ₃ HgCl	/	nd	nd	nd	-	-
CdCl ₂	181	19	108	41	nd	-	-
	19	380	37	37	4	+/-	-

continues

CaCl ₂	Kidney cells	/	nd	nd	nd	+	+	+
RbCl		/	nd	nd	nd	+	+	+
CrCl ₃		/	nd	nd	nd	+	+	+/
CuSO ₄		/	450	nd	nd	+/	+	-
K ₂ Cr ₂ O ₇		nd	/	nd	nd	-	-	/
CH ₃ HgCl		nd	/	nd	nd	-	-	/
CdCl ₂		nd	/	110	nd	-	-	/
NaAsO ₂		300	/	40	nd	+/	-	/
CaCl ₂	Lungs cells	/	nd	nd	nd	+	+	+/
RbCl		/	114	110	110	+	+	+/
CrCl ₃		/	35	199	199	+/	+	+/
CuSO ₄		/	901	132	132	+/	+	-
K ₂ Cr ₂ O ₇		13	/	nd	nd	-	-	/
CH ₃ HgCl		nd	/	nd	nd	-	-	/
CdCl ₂		64	/	415	415	-	-	/
NaAsO ₂		20	/	nd	nd	-	-	/
CaCl ₂	Bone marrow cells	/	nd	51	51	+	+	+/
RbCl		/	128	20	20	+	+	+/
CrCl ₃		/	21	21	21	+	+	+/
CuSO ₄		/	145	127	127	+	+	-
K ₂ Cr ₂ O ₇		nd	/	127	127	-	-	/
CH ₃ HgCl		nd	/	165	165	-	-	/
CdCl ₂		nd	/	nd	nd	-	-	/
NaAsO ₂		nd	/	nd	nd	+/	+	/

hGH levels in untreated cells medium (controls) were not measurable after 24-hour incubation.
 nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability;
 - = 100% dead

CLAIMS

1. A non-human transgenic animal which comprises cells containing a construct of a stress-sensitive regulatory sequence linked to a reporter-gene sequence.
5
2. A non-human transgenic animal according to claim 1, wherein said regulatory sequence is the heat shock protein (hsp) promoter.
3. A non-human transgenic animal according to claim 2,
10 wherein said sequence is hsp70 gene promoter.
4. A non-human transgenic animal according to claims 1-3, wherein said reporter gene is the growth hormone (GH) gene.
5. A non-human transgenic animal according to any of
15 the previous claims, which is a mammal.
6. A non-human transgenic animal according to claim 5, which is a rodent.
7. A non-human transgenic animal according to claim 6, which is a mouse.
- 20 8. A primary cell culture obtained from the transgenic animals of claims 1-7, wherein cells bear a construct of a stress-sensitive regulatory sequence linked to a reporter-gene sequence.
9. A primary cell culture according to claim 8, which
25 is a fibroblast, hepatocyte, kidney, lung and bone marrow-cell culture.
10. A method for the study of chemical, physical and biological toxic agents which comprises:
 - a) exposing the transgenic animal of claims 1-7
30 to the toxic agent;
 - b) determining the effect through measurement of

the reporter-gene expression.

11. A method according to claim 10, wherein the same animal is used for repeated tests with the same or different toxic agent.

5 12. A method according to claims 10-11, for the study of toxicity kinetics of one or more toxic agents.

13. A method according to claims 10-12, for the study of heat stress.

10 14. A method according to claims 10-12, for the study of metal toxicity.

15. A method according to claim 14 for the study of toxicity of metals selected from the group consisting of Rb, Cu, Hg, As and Cd.

15 16. A method for the toxicity study of chemical, physical and biological agents, which comprises:

20 a) preparing a primary culture from the transgenic animal of claims 1-7, in which the cultured cells bear a construct of a stress-sensitive regulatory sequence linked to a reporter-gene sequence;

b) exposing the primary culture to the toxic agent;

c) determining the effect through the expression of the reporter gene in the culture medium.

25 17. A method according to claim 16, wherein fibroblast and hepatocyte primary cultures are used.

18. A method according to claims 16-17 for the study of metal toxicity.

30 19. A method according to claim 18, wherein metals are selected from the group consisting of Rb, Cr, Cu, Hg, As, and Cd.


21

20. The use of the transgenic animal of claim 1 for in vivo toxicity studies.

21. The use of a transgenic animal according to claim 19, wherein said animal is a mouse..

5 22. The use of primary cultures of cells from the transgenic animal of claim 1, for in vitro toxicity studies.

FIGURE 1



2 / 4




FIGURE 2





FIGURE 4



INTERNATIONAL SEARCH REPORT

International Application No
PCT/IT 98/00231

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/00 A01K67/027 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUVEN, K. ET AL.: "Evaluation of a stress-inducible transgenic nematode strain for rapid aquatic toxicity testing" AQUATIC TOXICOLOGY, vol. 29, no. 1-2, June 1994, pages 119-137, XP002089378	1-3, 10-15, 20
Y	see the whole document ---	1-22
X	CA 2 088 379 A (CANDIDO EDWARD P M ;STRINGHAM EVE G (CA); JONES DONALD (CA)) 30 July 1994 see the whole document ---	1-3, 10-12, 20
Y	EP 0 336 523 A (INTRACEL CORP) 11 October 1989 see the whole document ---	1-22
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 January 1999

21/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 98/00231

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 263 908 A (BATTELLE MEMORIAL INSTITUTE) 20 April 1988 see the whole document ---	1-22
P, X	WO 98 28971 A (LINK CHRISTOPHER ;UNIV TECHNOLOGY CORP (US)) 9 July 1998 see the whole document ---	1-3, 10-12, 20
P, X	SACCO, M.G. ET AL.: "A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds" NATURE BIOTECHNOLOGY., vol. 15, no. 13, December 1997, pages 1392-1397, XP002089379 PUBLISHING US see the whole document -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 98/00231

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2088379 A	30-07-1994	NONE	
EP 0336523 A	11-10-1989	AU 3411889 A WO 8909822 A	03-11-1989 19-10-1989
EP 0263908 A	20-04-1988	AU 612607 B AU 8078487 A CA 1319631 A DE 3681738 D DK 320888 A WO 8802778 A EP 0285642 A JP 2509271 B JP 1501439 T US 5614381 A ZA 8707656 A	18-07-1991 06-05-1988 29-06-1993 31-10-1991 13-06-1988 21-04-1988 12-10-1988 19-06-1996 25-05-1989 25-03-1997 18-04-1988
WO 9828971 A	09-07-1998	AU 5619298 A	31-07-1998